CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MInfla-Tilc targets innate lymphoid cells 2 (ILC2s) to develop a new monoclonal antibody treatment for severe asthma. By focusing on these cells, the project aims to control inflammation and improve outcomes for patients suffering from allergic asthma.
We are proposing to target Innate Lymphoid Cells 2 (ILC2s), a subset that has been frequently implicated in inflammatory diseases, such as severe asthma. ILC2s are major players in allergic asthma and are abundantly present as tissue resident cells in the lung, both in human and mouse.
Strikingly, the induction of allergic asthma in a mouse model deficient in ILC2s is abolished.
In addition, the transfer of ILC2s back in the same mouse recapitulates the pathology.
Mechanistically, activated ILC2…
UNIVERSITE D'AIX MARSEILLE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
